Comparative Pharmacology
Head-to-head clinical analysis: CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE versus DORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE versus DORAL.
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE vs DORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their synaptic concentrations, while chlordiazepoxide potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
1 capsule (containing chlordiazepoxide 5 mg and amitriptyline HCl 12.5 mg) orally 3-4 times daily; may increase to 2 capsules (10 mg/25 mg) 3-4 times daily if needed.
15-30 mg orally at bedtime, maximum 60 mg/day.
None Documented
None Documented
Chlordiazepoxide: terminal half-life 5-30 hours (parent drug), 36-200 hours (active metabolite desmethylchlordiazepoxide); prolonged in elderly and liver disease. Amitriptyline: terminal half-life 13-36 hours (parent), 20-60 hours (active metabolite nortriptyline); dose adjustment needed for hepatic impairment.
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Chlordiazepoxide: renal excretion of metabolites (60-70% as conjugated metabolites, 1-2% unchanged); fecal excretion ~10%. Amitriptyline: renal excretion of metabolites (30-50% as glucuronides and sulfates, <2% unchanged); biliary/fecal excretion ~20-30%.
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Category D/X
Category C
Benzodiazepine
Benzodiazepine